|1.||Huang, Xiaodong: 1 article (07/2014)|
|2.||Zhang, Yixin: 1 article (07/2014)|
|3.||Cai, Jing: 1 article (07/2014)|
|4.||Cui, Xiaopeng: 1 article (07/2014)|
|5.||He, Song: 1 article (07/2014)|
|6.||Ni, Runzhou: 1 article (07/2014)|
|7.||Lu, Cuihua: 1 article (07/2014)|
|8.||Yang, Dunpeng: 1 article (07/2014)|
|9.||Lv, Liting: 1 article (07/2014)|
|10.||Cong, Xia: 1 article (07/2014)|
01/09/2007 - "Human glycinamide ribonucleotide transformylase (GART) (EC 220.127.116.11) is a validated target for cancer chemotherapy, but mechanistic studies of this therapeutically important enzyme are limited. "
01/01/1989 - "In vivo studies with 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), an inhibitor of glycinamide ribonucleotide transformylase, indicate that at doses ranging from 2.5 to 10 mg/kg, it prolongs the survival of mice implanted with L1210 tumors. "
12/14/1993 - "These data show that even for tumor cells with severely impaired antifolate transport, the extensive conversion of DDATHF to polyglutamyl forms required for GAR transformylase inhibition preserves high levels of antitumor activity."
06/01/1994 - "GAR transformylase activity was higher in colon 38 tumor than in liver, but a kinetic analysis on the purified enzyme showed no differences in Ki values for DDATHF or Km values for the folate substrate. "
01/01/1998 - "The whole-body autoradiographic distribution of two radiolabeled antifolate inhibitors of GAR formyltransferase, lometrexol and LY309887, were compared in tumor-bearing mice maintained on standard diet (SD) and a low-folate diet (LFD) in order to determine the total amounts of drug that accumulated in blood, tumor, liver and kidney. "
01/01/1991 - "The results suggest that GAR transformylase is a target for a series of compounds whose structures resemble that of tetrahydrofolate and indicate that the inhibition of GAR transformylase by these compounds is sufficient to induce the maturation of HL-60 leukemia cells."
01/01/1993 - "5,10-Dideazatetrahydrofolic acid (DDATHF) is an inhibitor of glycinamide ribonucleotide transformylase, the first of two tetrahydrofolate requiring enzymes in the de novo purine nucleotide biosynthetic pathway, and is a potent inducer of the maturation of HL-60 promyelocytic leukemia cells. "
01/15/2002 - "We determined the mechanisms of resistance of human CCRF-CEM leukemia cells to methotrexate (MTX) vs. those to six novel antifolates: the polyglutamatable thymidylate synthase (TS) inhibitors ZD1694, multitargeted antifolate, pemetrexed, ALIMTA (MTA) and GW1843U89, the non-polyglutamatable inhibitors of TS, ZD9331, and dihydrofolate reductase, PT523, as well as DDATHF, a polyglutamatable glycinamide ribonucleotide transformylase inhibitor. "
10/01/1986 - "This quinazoline folate analogue showed no activity as a substrate for the folate-requiring de novo purine biosynthetic enzyme glycinamide ribonucleotide transformylase isolated from the murine lymphoma cell line L5178Y, but proved to be a potent competitive inhibitor, Ki = 1.3 microM, of the purified enzyme."
03/12/1985 - "Glycinamide ribonucleotide transformylase, the first of the two formyl group transferases of de novo purine biosynthesis requiring 10-formyltetrahydrofolate, has been purified 1500-fold, nearly to homogeneity, from the murine lymphoma cell line L5178Y. "
|4.||Hepatocellular Carcinoma (Hepatoma)
03/15/1991 - "The NH2-terminal sequence (residues 1-203) is 24-30% identical to phosphoribosylglycinamide formyltransferase (EC 18.104.22.168) from Bacillus subtilis (30%), Escherichia coli (24%), Drosophila melanogaster (24%), and human hepatoma HepG2 (27%). "
07/01/2014 - "Increased expression of glycinamide ribonucleotide transformylase is associated with a poor prognosis in hepatocellular carcinoma, and it promotes liver cancer cell proliferation."
02/01/1996 - "Lometrexol (5,10-dideazatetrahydrofolic acid; DDATHF), is a specific inhibitor of glycinamideribonucleosyl (GAR) transformylase with anti-tumour activity in murine and human carcinomas. "
03/15/1994 - "We have investigated the potential of glycineamide ribonucleotide transformylase (GAR TFase) inhibitors to produce regressions in multiple preclinical models of colon carcinoma. "
|2.||Folic Acid (Vitamin M)
|9.||5,6,7,8-tetrahydrofolic acid (tetrahydrofolate)
|1.||Drug Therapy (Chemotherapy)